Quick answer
Trulicity (dulaglutide) and Ozempic injection (semaglutide) are different once-weekly GLP-1 medicines for type 2 diabetes. Semaglutide lowered A1C and weight more in the specific dose comparisons tested in SUSTAIN 7. That result does not identify the best medicine for every person or compare today's highest doses. Approved uses, medical history, side effects, the exact device and coverage also matter.[1–3]
This guide compares injections. It does not provide a prescription or a switching schedule.
Approved uses: the differences that matter
Both are used alongside diet and exercise for blood sugar control, but their approved populations differ.[1,2]
| Question | Trulicity | Ozempic injection |
|---|---|---|
| Blood sugar control | Adults and children aged 10 or older with type 2 diabetes | Adults with type 2 diabetes |
| Cardiovascular risk reduction | Adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors | Adults with type 2 diabetes and established cardiovascular disease |
| Kidney indication | No corresponding indication listed | Reduces the risk of sustained kidney-function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease |
| Chronic weight management | Not a listed indication | Not a listed indication |
| Injection presentations | Single-dose pens | Pens containing multiple weekly doses for one patient, and single-dose prefilled syringes |
Cardiovascular risk reduction here means reducing the risk of cardiovascular death, nonfatal heart attack or nonfatal stroke. Different approved uses do not establish that one medicine protects the heart or kidneys better than the other in a direct comparison.[1,2]
Do not assume Ozempic injection always comes as a pen. Ask the pharmacist which presentation you will receive and learn its specific instructions. A listed presentation does not establish local availability. Never share an Ozempic pen, even with a new needle.[2]
For the separate question about a single medicine and weight, read what the Trulicity label says about weight loss. For a separate comparison of semaglutide brands and their approved uses, see Wegovy vs Ozempic.
What did SUSTAIN 7 find?
The 40-week, open-label trial randomized 1,201 adults with type 2 diabetes inadequately controlled on metformin alone. At the two specific dose comparisons tested, semaglutide produced greater average reductions in A1C and body weight than dulaglutide. This finding does not rank every approved dose or establish the best medicine for an individual.[3]
Its primary analysis used measurements while participants were receiving treatment and before rescue medication. These findings come from the primary study abstract; we could not access the full report or complete missing-data methods. They do not establish device usability or heart and kidney superiority, and they do not cover today's highest labeled doses or people without diabetes. Novo Nordisk funded the trial. Gastrointestinal disorders were the most frequently reported adverse events and the most common reason for treatment discontinuation.[3]
A1C is a measure of blood sugar control. The study findings are not a dosing, equivalence or switching guide.
Side effects and warnings
Both medicines can cause nausea, vomiting, diarrhea and abdominal pain. Both labels warn about sometimes severe gastrointestinal reactions, pancreatitis, gallbladder disease, serious allergic reactions and kidney injury related to dehydration. Neither is recommended for severe gastroparesis, a condition involving markedly delayed stomach emptying.[1,2]
Both have a boxed warning about thyroid C-cell tumors observed in rodents; whether they cause these tumors in humans is unknown. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma, in people with multiple endocrine neoplasia syndrome type 2 (MEN2), and in people who have had a serious allergic reaction to that product or its ingredients. This does not mean every thyroid condition is a contraindication.[1,2]
Tell your clinician about diabetic retinopathy and any insulin or sulfonylurea use. Both labels discuss eye complications and an increased risk of low blood sugar, including severe episodes, with those diabetes medicines. Tell the procedural team about treatment before anesthesia or deep sedation because of aspiration risk. These labels do not establish a universal number of days to stop before a procedure.[1,2]
Seek help: for persistent or severe abdominal pain, sometimes reaching the back, with or without nausea or vomiting, stop the medicine and contact a clinician promptly for possible pancreatitis. For a serious allergic reaction, such as trouble breathing or swelling of the face, tongue or throat, stop the medicine and get medical help right away.[1,2]
Separate adverse-event tables from different drug-label trials cannot establish which medicine is safer for you.
Print or copy this appointment card
Bring the card and a full medication list to your clinician or pharmacist.
- My current medicine, dose and how long I have used it: __________
- My priorities and recent A1C or weight trend: __________
- Heart, kidney, eye, stomach, pancreas or gallbladder history to discuss: __________
- Pregnancy, breastfeeding or pregnancy plans to discuss: __________
- Which approved use fits my situation, and which exact presentation will I receive?
- What monitoring and follow-up do I need? Which symptoms require urgent help?
- If coverage or tolerability is a problem, whom should I contact before making a change?
Ask the pharmacist or insurer to check the exact prescription, formulary, prior authorization, quantity and savings eligibility. This article does not quote a price or guarantee coverage or supply.
Do not make routine medication changes from these study findings; ask your prescriber for an individual plan. The urgent-symptom advice above still applies.
Frequently Asked Questions
Are Trulicity and Ozempic the same medicine?
No. They have different active ingredients, approved populations and presentations. Their doses are not interchangeable milligram for milligram.[1,2]
Which led to more weight loss in SUSTAIN 7?
Semaglutide produced greater mean weight reduction in the specific dose comparisons tested in that trial. Neither injection label lists chronic weight management, and the trial does not answer which medicine is best for an individual.[1–3]
Can I switch using the same dose?
This article provides no equivalent dose or switching schedule. Your prescriber must decide whether and how to change treatment.[1,2]
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.Trulicity U.S. prescribing information, revised March 2026 · Eli Lilly and Company · accessed
- 2.Ozempic injection U.S. prescribing information, revised May 2026 · Novo Nordisk · accessed
- 3.Pratley et al. SUSTAIN 7 primary study abstract · The Lancet Diabetes & Endocrinology, 2018 · accessed
Telehealth prescribing rules differ by state. Read the state-by-state guide.
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them